Raymond James Financial
CLLS

Raymond James Financial’s Cellectis CLLS Stock Holding History

Raymond James Financial’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,132
Closed -$1.73K – 5301
2025
Q2 		$1.73K Buy
+1,132
New +$1.64K ﹤0.01% 6444

Other funds holding CLLS

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Raymond James Financial's CLLS Position: Q3 2025 in Review

Raymond James Financial sold out of Cellectis (CLLS) in Q3 2025, closing a stake of 1,132 shares — an estimated $1.73K sold.

Raymond James Financial first reported a position in CLLS in Q2 2025 and held it in 1 quarter. The position peaked at $1.73K in Q2 2025. 28 funds tracked by Wall St. Rank hold CLLS as of Q3 2025.

  • Raymond James Financial reported no remaining Cellectis position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,132 Cellectis shares in Q3 2025, an estimated $1.73K.
  • Raymond James Financial first reported a position in Cellectis in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Cellectis position peaked at $1.73K in Q2 2025.
  • 28 funds tracked by Wall St. Rank held Cellectis as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.